Furthermore, the analysis of aberrant hypermethylation of Dab2 promotor were performed in Nasopharyngeal carcinomas, Esophageal Squamous Cell Cancers, breast cancers and lung cancers, respectively. This evidence concerns the gene DAB2 and breast carcinoma.